Literature DB >> 3318457

Fibric acids: effects on lipids and lipoprotein metabolism.

S M Grundy1, G L Vega.   

Abstract

The major effect of the fibrates on triglycerides is to promote triglyceride-rich lipoprotein catabolism through increased lipoprotein lipase activity. Fibrates also enhance lipolysis of plasma triglycerides by a means different from that of caloric restriction. Their effect on very low-density lipoprotein metabolism also differs from that of nicotinic acid. The effect of fibrate therapy upon low-density lipoprotein-cholesterol concentrations depends upon the patients' overall lipoprotein status. The responsible mechanisms are not understood. In hypertriglyceridemic patients, fibrates often reverse abnormal changes in low-density lipoprotein composition; low-density lipoprotein heterogeneity is reduced and small dense low-density lipoproteins are eliminated, apparently secondary to reduced levels of triglyceride-rich lipoproteins. Kinetic studies indicate that fibrates do not enhance low-density lipoprotein formation rates, thus contradicting the idea that fibrate therapy causes increased low-density lipoprotein cholesterol levels via increased conversion of very low-density lipoprotein to low-density lipoprotein. Though enhanced low-density lipoprotein catabolism in hypertriglyceridemia could occur via several mechanisms, the responsible factors are largely reversed by fibrate therapy. In non-hypertriglyceridemic patients, fibrates may actually enhance the fractional clearance of low-density lipoprotein and thus reduce low-density lipoprotein levels. Fibrate therapy reverses the typical high-density lipoprotein pattern of hypertriglyceridemic patients, producing more high-density lipoprotein2a and less high-density lipoprotein2b. Such treatment also increases high-density lipoprotein cholesterol levels in patients without definite hypertriglyceridemia. Synthesis rates of apolipoproteins AI and AII may be affected by fibrates. The fibrates' major effects on sterol metabolism are interference with cholesterol and bile acid synthesis and increased cholesterol secretion into bile. Although bile saturation increases in most patients, in only a relatively small percentage do gallstones actually develop; super-saturated bile is not sufficient to induce gallstone formation in most patients. Available data strongly imply that fibrates mobilized cholesterol out of tissue pools, perhaps by altering tissue cell membranes to allow cholesterol release from the cell surfaces.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318457     DOI: 10.1016/0002-9343(87)90866-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

1.  Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.

Authors:  L Kłosiewicz-Latoszek; W B Szostak
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.

Authors:  M Shimada; S Ishibashi; T Inaba; H Yagyu; K Harada; J I Osuga; K Ohashi; Y Yazaki; N Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

Authors:  György Paragh; Ildikó Seres; Mariann Harangi; Annamária Erdei; Mária Audikovszky; Lóránd Debreczeni; Anna Kovácsay; László Illyés; Gyula Pados
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

4.  Fibrates and HMG-CoA reductase inhibitors.

Authors:  M W Huff
Journal:  CMAJ       Date:  1991-10-15       Impact factor: 8.262

5.  Treatment targets in the management of dyslipidemias: which targets in whom?

Authors:  Scott M Grundy
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

6.  Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).

Authors:  R Bergemann; A Brandt; W Siegrist
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

7.  Reduction of BM 15.766-induced 7-dehydrocholesterol accumulation by bezafibrate and mevinolin in rats. A non-isotopic in vivo test system for compounds reducing cholesterol synthesis.

Authors:  J Pill; E C Witte; F H Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

Review 8.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 9.  Fenofibrate and Dyslipidemia: Still a Place in Therapy?

Authors:  Nicola Tarantino; Francesco Santoro; Michele Correale; Luisa De Gennaro; Silvio Romano; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 10.  Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.

Authors:  G D'Amico
Journal:  Klin Wochenschr       Date:  1991-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.